Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. - Wikidata - awgldk - TriplyDB

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

http://www.wikidata.org/entity/Q39432471

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model The NF-κB Pathway and Cancer Stem Cells Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers PI3K and AKT: Unfaithful Partners in Cancer Ligand-Independent EGFR Signaling Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date The role of NF-κB in the pathogenesis of glioma NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.Akt1 enhances CA916798 expression through mTOR pathway A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling mTORC2 in the center of cancer metabolic reprogramming mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells TORC2-a new player in genome stability Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel.Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.Conditional astroglial Rictor overexpression induces malignant glioma in mice The mTOR signaling pathway as a treatment target for intracranial neoplasms Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.Significance of filamin A in mTORC2 function in glioblastoma Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition.Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.

P2860

Q21133610-752331F7-26E9-4C9D-9CD0-F7131799F181 Q26750605-FCC7F8D5-9484-4624-98B0-F596E62BA7FC Q26751473-5B5927A9-2A24-44F5-A832-1F0EAFE17B89 Q26781367-618865C9-29E6-436D-A6A0-F3EEF975545D Q26797495-5BD4ECFB-0FBC-49F2-B9D2-244179CB96AD Q26822717-C56A4D23-6AB7-40BB-B036-9F5AE61837FC Q26825502-75F4B5C0-454F-4DAD-9826-36D160329D02 Q26830388-5DC1F0F9-43E7-462C-AA50-ABAF3CBB27CC Q27013006-E9456CA9-9ED6-4BF3-A778-728CC1A8B433 Q27015045-4825A008-A957-4910-9FA8-3EBDEB37C8A4 Q27324733-409653C9-249E-4241-8D40-45FA59CD31D6 Q28087306-ECC086C7-2275-4BC3-B2A6-F4E3BBCFF65C Q28115436-0D6530B3-97E1-47AD-BF1E-CF4B393D82CE Q28487802-F8A46A32-6CD7-4F14-B1DC-6FB077B2A092 Q30396975-23851984-0630-4173-BCBC-EC6068D9B52D Q33276239-9F630725-9918-4067-BABD-25A3D7677D4B Q33435610-39492EFC-D853-4EBD-BD59-D854EDE14CBC Q33466722-0CB5E248-B660-4B51-A2E3-4C33E74F0AB3 Q33615797-836E6196-DCF4-41FD-969A-30301711D40E Q33643498-F9B9D2F1-DC2A-47AC-B2F7-EE3D1D68B05F Q33798469-8633C53C-4191-45FC-A300-C186423D3E78 Q33831466-EF253059-3B05-4077-88B0-2A56B670ECA7 Q33884658-62BD44A3-C45D-4DEB-9A7B-24FB5BD66D22 Q33925544-69F26FF5-DE6B-4C52-BB04-8618A8B530AE Q34060669-3DB952C8-CE02-4C9E-864D-D719663E9187 Q34131149-8F9A4447-81CE-4F6D-AC92-BDED0EBC6B23 Q34143354-62087C62-17C1-4F21-AED0-5E7ACBFE3548 Q34293127-6D020A5E-47D7-410C-ABDB-74E61C28BA14 Q34365897-4BABE180-DAFC-413F-90E2-137FC52F491B Q34394233-224FD87C-8FAB-4DD7-9FED-F74471E6BA20 Q34451068-083F00D8-B9EF-4002-9176-8D4B915593FA Q34886859-AD5DA205-8CAC-4A30-AC62-214D4822B7FB Q34974398-CC0FFBDC-22C8-4CBC-969F-EE06FD1854F0 Q34986247-964C4B49-5E84-44FD-AB9E-270D49BDA76C Q35287890-0B7E77D2-7627-4BBD-A1F5-DB8920FFE70C Q35408838-52964784-49D8-40A4-99E3-19781DB9602E Q35809950-5BF52EB8-F5DB-4561-A096-5F88E9AA43E6 Q35828426-33FA7BA3-38A5-4542-BCE7-77593F78FEE5 Q35843230-B130947D-EDC6-40F5-A02C-4D285A8238C0 Q35910243-53AE21F8-1605-4C5A-A139-AB55097937F8

P2860

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

http://www.wikidata.org/entity/Q39432471

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.

@en

Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.

@nl

type

label

Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.

@en

Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.

@nl

prefLabel

Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.

@en

Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.

@nl

P1433

Q39432471-E4A68BA5-2E9B-423A-BA55-7B3AD166320A

P1476

Q39432471-BB14FC55-7D36-4585-AC63-EEF922095F4B

P2093

Q39432471-0C4EECC0-9B53-4744-93EE-491D4B39A5CC

Q39432471-12875FB8-E4B3-48EF-9AF1-56A0EE57515B

Q39432471-195CF579-7059-4020-B33B-B10C7C97DB55

Q39432471-1F0450BA-0D1B-485A-8467-C8985C4F3F60

Q39432471-3A44BC4A-F1EE-46BF-9E54-A2835F990F4C

Q39432471-3B189B6E-71F6-45CA-8AF0-D66FD896BE6A

Q39432471-3EFA7830-9E67-4307-9B43-2D9A34411720

Q39432471-7499C636-A1AB-40E0-8CAB-48F042C11852

Q39432471-774AEA82-22A7-4C51-9592-DA764E3DD1AB

Q39432471-88A679DA-1A9E-49A2-8439-C7BD02DCC257

P2860

Q39432471-03239896-C5AB-4251-8DF8-4D3CA0308431

Q39432471-0A880052-0C39-497A-909E-206B7AE02D35

Q39432471-0AE5E7C9-4464-4878-B4F8-C4D37AB72E5E

Q39432471-0FDC8FF9-09D4-4FC7-B6F8-F539A62ABFB2

Q39432471-0FF4A826-DCE0-4C49-9F58-5CB5E87B5E39

Q39432471-119B9BBD-4DD3-4A28-B4A4-8D58FA310758

Q39432471-34027B9A-465E-4E98-9AD8-B9F5623AE4BE

Q39432471-343A8428-B1AE-4577-9B6B-899D09D503B6

Q39432471-34C61838-752F-4BA0-A8FD-5EFAE0752E87

Q39432471-36048121-8633-41F7-B00A-9FB97B482A01

P304

Q39432471-B34B88B4-729C-4F8C-A199-4A5E86C84EAA

P31

Q39432471-19459B63-C86F-4BDA-830A-CFAD59422957

P356

Q39432471-677AA80F-C710-4498-A635-420F9C9FCD03

P433

Q39432471-42448DFA-E1C6-425B-9545-A8FB8D4FC523

P478

Q39432471-DB447BDE-AE10-4F01-86B0-7B85869C1FB3

P50

Q39432471-9676E305-A1C9-4E42-ABEB-46AA4B186F86

P577

Q39432471-0BE2F3E1-2B1A-4840-A24F-72EBD9CACA8C

P5875

Q39432471-7A91F6D3-7B2B-439C-9C7C-D72DFDB1471D

P698

Q39432471-6B25EADC-5159-40EA-8FA2-4B83A95C4F1F

P921

Q39432471-726ADE84-1E1C-465A-8E40-92199BE66934

Q39432471-BA35356C-9839-4280-BD74-DE87966A1DD4

P932

Q39432471-A2CDC185-D719-4672-8532-F3B757075CFB

P356

2159-8290.CD-11-0124

P1433

Cancer Discovery

P1476

Oncogenic EGFR signaling activ ...... motes chemotherapy resistance.

@en

P2093

Albert S Baldwin

http://www.w3.org/2001/XMLSchema#string

Ali Nael Amzajerdi

http://www.w3.org/2001/XMLSchema#string

Amanda Rinkenbaugh

http://www.w3.org/2001/XMLSchema#string

Beatrice Gini

http://www.w3.org/2001/XMLSchema#string

Brendan D Manning

http://www.w3.org/2001/XMLSchema#string

Christian C Dibble

http://www.w3.org/2001/XMLSchema#string

David Akhavan

http://www.w3.org/2001/XMLSchema#string

David Nathanson

http://www.w3.org/2001/XMLSchema#string

Deliang Guo

http://www.w3.org/2001/XMLSchema#string

Hancai Dan

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Activation of mTORC2 by association with the ribosome

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Mechanism of activation of protein kinase B by insulin and IGF-1

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

P304

524-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-11-0124

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Harry V Vinters

P577

2011-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51856097

http://www.w3.org/2001/XMLSchema#string

P698

22145100

http://www.w3.org/2001/XMLSchema#string

P921

P932

3229221

http://www.w3.org/2001/XMLSchema#string